News · 26 weeks48+67%
2026-04-192026-10-11
Mix1990d
- SEC Filings11(58%)
- Other3(16%)
- Earnings2(11%)
- Insider1(5%)
- Leadership1(5%)
- Analyst1(5%)
Latest news
25 items- PRNEXGEL Announces 1-for-20 Reverse Stock Split EffectivenessSplit-adjusted trading to begin on The Nasdaq Capital Market at market open on October 12, 2026 LANGHORNE, Pa., Oct. 12, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a company with a patient centric medical technology sales and marketing team working closely with clinicians to provide solutions that drive better outcomes, streamline care, and elevate the patient experience, today announced that its common stock, par value $0.001 per share (the "Common Stock"), will begin trading on a split-adjusted basis on The Nasdaq Capital Market at the opening of trading today, following the effectiveness of a previously announced 1-for-20 reverse stock split of
- SECSEC Form 8-K filed by NexGel Inc8-K - NEXGEL, INC. (0001468929) (Filer)
- SECNexGel Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - NEXGEL, INC. (0001468929) (Filer)
- SECNexGel Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - NEXGEL, INC. (0001468929) (Filer)
- PRNEXGEL Announces Dial-In Details for Investor Update CallLANGHORNE, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a company with a patient centric medical technology sales and marketing team working closely with clinicians to provide solutions that drive better outcomes, streamline care, and elevate the patient experience, today announced dial-in details for its previously announced investor update call to be held on September 24, 2026, at 4:15 p.m. Eastern Time. Investor Update Call Details Date: September 24, 2026Time: 4:15 p.m. Eastern TimeLive Call: 1-833-309-3473 (U.S. Toll Free) or 1-785-838-9251 (International)Conference ID: NEXGEL For interested individuals unable to join the confer
- PRNEXGEL Announces Date for Investor Update CallLANGHORNE, Pa., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a company with a patient centric medical technology sales and marketing team working closely with clinicians to provide solutions that drive better outcomes, streamline care, and elevate the patient experience, today announced the date for the investor update call referenced in its August 17, 2026 earnings release, at which time the Company indicated it expected to host the call on or around September 15, 2026. The Company will now host the call on September 24, 2026, at 4:15 p.m. Eastern Time. The call will provide investors with an update on the Company's operational progress, c
- SECSEC Form DEF 14A filed by NexGel IncDEF 14A - NEXGEL, INC. (0001468929) (Filer)
- ANALYSTNexGel downgraded by Maxim GroupMaxim Group downgraded NexGel from Buy to Hold
- SECNexGel Inc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - NEXGEL, INC. (0001468929) (Filer)
- PRNEXGEL ANNOUNCES LEADERSHIP TRANSITION AND STRATEGIC REVIEW INITIATIVELANGHORNE, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL") today announced a series of leadership, governance and strategic initiatives designed to strengthen operational execution, improve liquidity, and enhance long-term shareholder value. The actions include the appointment of Brian Kieser as Interim Chief Executive Officer and the formation of a Special Committee for Strategic Review and Value Creation. Leadership Transition Effective August 21, 2026, Brian Kieser has been appointed Interim Chief Executive Officer of NEXGEL. Following the Company's April 2026 acquisition of certain assets from Celularity, Inc., Mr. Kieser became acti
- SECSEC Form S-1 filed by NexGel IncS-1 - NEXGEL, INC. (0001468929) (Filer)
- SECNexGel Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - NEXGEL, INC. (0001468929) (Filer)
- PRNEXGEL Reports Second Quarter 2026 Financial ResultsLANGHORNE, Pa., Aug. 17, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its second quarter 2026 financial results for the period ending June 30, 2026. The second quarter of 2026 was a period of significant transformation and preparation for NexGel. Following the completion of our transaction with Celularity, Inc. in mid-April, the Company focused on transitioning employees, integrating sales representatives and customer relationships, and aligning our marketi
- SECSEC Form 10-Q filed by NexGel Inc10-Q - NEXGEL, INC. (0001468929) (Filer)
- SECSEC Form NT 10-Q filed by NexGel IncNT 10-Q - NEXGEL, INC. (0001468929) (Filer)
- SECSEC Form PRE 14A filed by NexGel IncPRE 14A - NEXGEL, INC. (0001468929) (Filer)
- SECNexGel Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - NEXGEL, INC. (0001468929) (Filer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Levy Adam R.4 - NEXGEL, INC. (0001468929) (Issuer)
- SECNexGel Inc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - NEXGEL, INC. (0001468929) (Filer)
- SECSEC Form 8-K filed by NexGel Inc8-K - NEXGEL, INC. (0001468929) (Filer)
- SECSEC Form 8-K filed by NexGel Inc8-K - NEXGEL, INC. (0001468929) (Filer)
- INSIDERChief Executive Officer Levy Adam R. sold $6,519 worth of shares (11,000 units at $0.59), decreasing direct ownership by 3% to 322,692 units (SEC Form 4)4 - NEXGEL, INC. (0001468929) (Issuer)
- SECNexGel Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - NEXGEL, INC. (0001468929) (Filer)
- INSIDERChief Executive Officer Levy Adam R. sold $1,841 worth of shares (3,000 units at $0.61), decreasing direct ownership by 0.89% to 333,692 units (SEC Form 4)4 - NEXGEL, INC. (0001468929) (Issuer)
- INSIDERChief Executive Officer Levy Adam R. sold $3,422 worth of shares (6,000 units at $0.57), decreasing direct ownership by 2% to 336,692 units (SEC Form 4)4 - NEXGEL, INC. (0001468929) (Issuer)
NXGL FAQ
7 questionsWhat does NexGel Inc do?
NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was founded in 1997 and is based in Langhorne, Pennsylvania.Where does NXGL stock trade?
NexGel Inc (NXGL) is listed on NASDAQ.What sector and industry is NXGL in?
NexGel Inc operates in the Health Care sector, Medical/Dental Instruments industry.When did NexGel Inc go public?
NexGel Inc (NXGL) completed its IPO in 2021.What are analysts saying about NXGL?
NexGel Inc has had 2 recent analyst actions on file. The most recent action was from Maxim Group: Hold on 2026-08-24. Recent price targets cluster around $600.00.What companies are similar to NXGL?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare NXGL side-by-side with any of them on Quantisnow.How can I track NXGL on Quantisnow?
Quantisnow aggregates NexGel Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NXGL to receive live email and push alerts on every new disclosure.